Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF

Authors

  • Silvia I. Anghel,

    1.  Departments of Dermatology and Venereology, Microbiology and Molecular Medicine, University Hospitals and Medical School of Geneva, Geneva, Switzerland
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Rafael Correa-Rochal,

    1.  Departments of Dermatology and Venereology, Microbiology and Molecular Medicine, University Hospitals and Medical School of Geneva, Geneva, Switzerland
    2.  Laboratory of Molecular Immunobiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Eva Budinska,

    1.  Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland
    2.  Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
    Search for more papers by this author
  • Kayluz F. Boliganl,

    1.  Departments of Dermatology and Venereology, Microbiology and Molecular Medicine, University Hospitals and Medical School of Geneva, Geneva, Switzerland
    2.  Department of Basic Research, National Institute of Oncology and Radiobiology, Havana, Cuba
    Search for more papers by this author
  • Shahnaz Abraham,

    1.  Departments of Dermatology and Venereology, Microbiology and Molecular Medicine, University Hospitals and Medical School of Geneva, Geneva, Switzerland
    Search for more papers by this author
  • Sara Colombetti,

    1.  Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland
    Search for more papers by this author
  • Lionel Fontao,

    1.  Departments of Dermatology and Venereology, Microbiology and Molecular Medicine, University Hospitals and Medical School of Geneva, Geneva, Switzerland
    Search for more papers by this author
  • Agnese Mariotti,

    1.  Division of Experimental Oncology, Faculty of Biology and Medicine, University of Lausanne, Epalinges, Switzerland
    Search for more papers by this author
  • Donata Rimoldi,

    1.  Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland
    Search for more papers by this author
  • Ghanem E. Ghanem,

    1.  Laboratoire d’Oncologie et Chirurgie Expérimentale, Institut J. Bordet, Université Libre de Bruxelles, Bruxelles, Belgium
    Search for more papers by this author
  • David E. Fisher,

    1.  Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Search for more papers by this author
  • Frederic Lévy,

    1.  Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland
    2.  Debiopharm SA, Lausanne, Switzerland
    Search for more papers by this author
  • Mauro Delorenzi,

    1.  Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, Switzerland
    2.  Département de Formation et Recherche, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    3.  National Center of Competence in Research (Molecular Oncology), ISREC-SV-EPFL, Lausanne, Switzerland
    Search for more papers by this author
  • Vincent Piguet

    1.  Departments of Dermatology and Venereology, Microbiology and Molecular Medicine, University Hospitals and Medical School of Geneva, Geneva, Switzerland
    2.  Department of Dermatology and Wound Healing, Cardiff Institute of Infection and Immunity, Cardiff University and University Hospital of Wales, Cardiff, UK
    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Erratum Volume 25, Issue 6, 834, Article first published online: 19 October 2012

Vincent Piguet, e-mail: piguetv@cardiff.ac.uk

Summary

Understanding the molecular aberrations involved in the development and progression of metastatic melanoma (MM) is essential for a better diagnosis and targeted therapy. We identified breast cancer suppressor candidate-1 (BCSC-1) as a novel tumor suppressor in melanoma. BCSC-1 expression is decreased in human MM, and its ectopic expression in MM–derived cell lines blocks tumor formation in vivo and melanoma cell proliferation in vitro while increasing cell migration. We demonstrate that BCSC-1 binds to Sox10, which down regulates MITF, and results in a switch of melanoma cells from a proliferative to a migratory phenotype. In conclusion, we have identified BCSC-1 as a tumor suppressor in melanoma and as a novel regulator of the MITF pathway.

Ancillary